Protein therapeutics: a summary and pharmacological classification
暂无分享,去创建一个
[1] Stgrp Capture,et al. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study , 1997, The Lancet.
[2] David C James,et al. Engineering mammalian cell factories for improved recombinant monoclonal antibody production: lessons from nature? , 2005, Biotechnology and bioengineering.
[3] E. Erba,et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone , 2001, British journal of haematology.
[4] P. Backeljauw,et al. Therapy for 6.5-7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study. , 2001, The Journal of clinical endocrinology and metabolism.
[5] R. Lisker,et al. Enzyme replacement therapy for primary adult lactase deficiency. Effective reduction of lactose malabsorption and milk intolerance by direct addition of beta-galactosidase to milk at mealtime. , 1984, Gastroenterology.
[6] P. Wax,et al. Initial postmarketing experience with crotalidae polyvalent immune Fab for treatment of rattlesnake envenomation. , 2002, Annals of emergency medicine.
[7] Elizabeth Pennisi,et al. Gene Counters Struggle to Get the Right Answer , 2003, Science.
[8] Armando Santoro,et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.
[9] A. Ganser,et al. A Randomized , Double-Blind , Placebo-Controlled , Phase III Study of Filgrastim in Remission Induction and Consolidation Therapy for Adults With De Novo Acute Myeloid Leukemia , 1997 .
[10] A. Sherman,et al. Transgenic chickens as bioreactors for protein-based drugs. , 2005, Drug discovery today.
[11] M. Shiffman,et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. , 2000, The New England journal of medicine.
[12] G. Cutler,et al. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty. , 1999, The Journal of clinical endocrinology and metabolism.
[13] M. Kaminski,et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. , 2000, Blood.
[14] M. Mascelli,et al. Molecular, Biologic, and Pharmacokinetic Properties of Monoclonal Antibodies: Impact of These Parameters on Early Clinical Development , 2007, Journal of clinical pharmacology.
[15] E. Frenkel,et al. Detection and Staging of Small Cell Lung Carcinoma with a Technetium‐labeled Monoclonal Antibody A Comparison with Standard Staging Methods , 1992, Clinical nuclear medicine.
[16] H A Vrooman,et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. , 1999, American journal of respiratory and critical care medicine.
[17] J. Burke,et al. A clinical evaluation of enzymatic debridement with papain-urea-chlorophyllin ointment. , 1958, American journal of surgery.
[18] D. Howrie. Growth hormone for the treatment of growth failure in children. , 1987, Clinical pharmacy.
[19] S. Rosenberg,et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. , 1994, Journal of the National Cancer Institute.
[20] J. Montaner,et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. , 2003, The New England journal of medicine.
[21] A. Riggs,et al. Expression in Escherichia coli of chemically synthesized genes for human insulin. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[22] C. Begley,et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. , 2002, Blood.
[23] P. Lipsky,et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial , 1999, The Lancet.
[24] T. Speroff,et al. Effect of growth hormone therapy on height in children with idiopathic short stature: a meta-analysis. , 2002, Archives of pediatrics & adolescent medicine.
[25] R. Colvin,et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. , 1981, Transplantation.
[26] D. Manninen,et al. The Quality of Life of Hemodialysis Recipients Treated With Recombinant Human Erythropoietin , 1990 .
[27] J. V. Moran,et al. Initial sequencing and analysis of the human genome. , 2001, Nature.
[28] B. Richter,et al. 'Human' insulin versus animal insulin in people with diabetes mellitus. , 2005, The Cochrane database of systematic reviews.
[29] Sante Tura,et al. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. , 1994, The New England journal of medicine.
[30] T. Simon,et al. Urokinase in pulmonary embolism. , 1973, Lancet.
[31] K. Öberg. Neuroendocrine gastrointestinal tumours , 1996 .
[32] Christopher T. Walsh,et al. Posttranslational Modification of Proteins: Expanding Nature's Inventory , 2005 .
[33] Christine Katlama,et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. , 2003, The New England journal of medicine.
[34] T. Wieman. Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group. , 1998, American journal of surgery.
[35] H. Milgrom,et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). , 2001, Pediatrics.
[36] F. Werf. A Comparison of Continuous Infusion of Alteplase with Double-Bolus Administration for Acute Myocardial Infarction , 1998 .
[37] M. Kaplan,et al. Treatment of chronic hepatitis C with interferon alfa‐n3: A multicenter, randomized, open‐label trial , 1997, Hepatology.
[38] M. Oken,et al. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. , 1992, The New England journal of medicine.
[39] Janice M. Reichert,et al. Development trends for monoclonal antibody cancer therapeutics , 2007, Nature Reviews Drug Discovery.
[40] L. Moreland,et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate , 2004, Annals of the rheumatic diseases.
[41] C. P. Morris,et al. Human alpha-L-iduronidase: cDNA isolation and expression. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[42] W. Gulliver,et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. , 2002, Journal of the American Academy of Dermatology.
[43] T. Casale,et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. , 2001, JAMA.
[44] I Royston,et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. , 1997, Blood.
[45] G. Cheng,et al. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. , 2005, Cancer research.
[46] L. Morales. Gaucher's Disease: A Review , 1996, The Annals of pharmacotherapy.
[47] M. J. Carson,et al. Clinical studies with glucagon in children. , 1955, The Journal of pediatrics.
[48] A. Oseroff,et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] E. Antman,et al. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. , 1990, Circulation.
[50] L. Gordon,et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] J H Simon,et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. , 2000, The New England journal of medicine.
[52] M. Dougados,et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. , 2005, The New England journal of medicine.
[53] Lars Bäckman,et al. INTERLEUKIN-2-RECEPTOR BLOCKADE WITH DACLIZUMAB TO PREVENT ACUTE REJECTION IN RENAL TRANSPLANTATION , 1998 .
[54] G. Krueger,et al. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. , 2001, The New England journal of medicine.
[55] L. O. C. Aplan,et al. SAFETY AND EFFICACY OF RECOMBINANT HUMAN a -GALACTOSIDASE A REPLACEMENT THERAPY IN FABRY'S DISEASE , 2001 .
[56] E. Arvat,et al. New approach to the diagnosis of growth hormone deficiency in adults. , 1996, European journal of endocrinology.
[57] Seth M Steinberg,et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.
[58] J L Ritchie,et al. Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. , 1983, The New England journal of medicine.
[59] Lyndsay N Harris,et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] D. Häussinger,et al. Gaucher's disease: a review for the internist and hepatologist. , 2000, Hepato-gastroenterology.
[61] M. Giral,et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. , 1990, The New England journal of medicine.
[62] D. F. Moore,et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. , 2001, JAMA.
[63] J. A. Scarlett,et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist , 2001, The Lancet.
[64] R. Bilous,et al. HUMAN INSULIN PRODUCED BY RECOMBINANT DNA TECHNOLOGY: SAFETY AND HYPOGLYCÆMIC POTENCY IN HEALTHY MEN , 1980, The Lancet.
[65] R. Rodriguiz,et al. Recombinant human interferon gamma therapy for osteopetrosis. , 1992, The Journal of pediatrics.
[66] Anthony J. Wilkinson,et al. Protein engineering 20 years on , 2002, Nature Reviews Molecular Cell Biology.
[67] J. Anderson,et al. Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: controlled comparison with intracoronary streptokinase. , 1988, Journal of the American College of Cardiology.
[68] E. Tanzi,et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. , 1994, The New England journal of medicine.
[69] E. Haber,et al. Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. , 1976, The New England journal of medicine.
[70] A. Menter,et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. , 2003, JAMA.
[71] R N Maini,et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.
[72] A. Ravaud,et al. Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma , 1998 .
[73] M. Weisman,et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. , 2003, Arthritis and rheumatism.
[74] S. Kemp,et al. Efficacy and safety of mecasermin rinfabate , 2006, Expert opinion on biological therapy.
[75] E. Schiff,et al. A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis B , 1990 .
[76] R. Taillefer,et al. Results of the Phase 3 Multicenter Clinical Trial Comparing 99mTc-Apcitide Scintigraphy with Contrast Venography for Imaging Acute DVT , 2000 .
[77] M. Hayden,et al. Murine α-l-Iduronidase: cDNA isolation and expression , 1994 .
[78] Michael Greenberg,et al. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes , 2004, Nature Reviews Drug Discovery.
[79] J. Vermylen,et al. A Higher than Expected Incidence of Factor VIII Inhibitors in Multitransfused Haemophilia A Patients Treated with an Intermediate Purity Pasteurized Factor VIII Concentrate , 1993, Thrombosis and Haemostasis.
[80] I. Mahmood,et al. Pharmacokinetic and Pharmacodynamic Considerations in the Development of Therapeutic Proteins , 2005, Clinical pharmacokinetics.
[81] E. Antman,et al. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. , 1999, Circulation.
[82] Linda Sher,et al. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. , 1994, The New England journal of medicine.
[83] M. Clark,et al. Antibody humanization: a case of the 'Emperor's new clothes'? , 2000, Immunology today.
[84] H. Ochs,et al. Octagam® 5%, an Intravenous IgG Product, Is Efficacious and Well Tolerated in Subjects with Primary Immunodeficiency Diseases , 2004, Journal of Clinical Immunology.
[85] P. Mannucci,et al. Treatment of congenital antithrombin III deficiency with concentrates , 1982, British journal of haematology.
[86] P. Kulkarni,et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. , 2002, The Journal of clinical endocrinology and metabolism.
[87] S. Govender,et al. Staged reduction and stabilisation in chronic atlantoaxial rotatory fixation. , 2002, The Journal of bone and joint surgery. British volume.
[88] R. Goode,et al. VITAMIN E AND OXYGEN CONSUMPTION , 1974 .
[89] P. Sönksen,et al. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. , 1989, The New England journal of medicine.
[90] T. Voit,et al. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial , 2005, Neuromuscular Disorders.
[91] U. Hedner. Dosing with recombinant factor viia based on current evidence. , 2004, Seminars in hematology.
[92] J. Åman,et al. Hypoglycaemia in Childhood Diabetes II. , 1988, Acta paediatrica Scandinavica.
[93] M. Lebwohl,et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. , 2003, The New England journal of medicine.
[94] M. Rennels,et al. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. , 2003, Pediatrics.
[95] C. Eng,et al. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. , 2001, The New England journal of medicine.
[96] C. Ponticelli,et al. Increased detection of antibody to hepatitis C virus in renal transplant patients by third-generation assays. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[97] A. Tashjian,et al. Erratum: Teriparatide human PTH(1-34): 2.5 Years of experience on the use and safety of the drug for the treatment of osteoporosis (Journal of Bone and Mineral Research (March 2006) 21 (354-365)) , 2006 .
[98] S. Baron,et al. The interferons. Mechanisms of action and clinical applications. , 1991, JAMA.
[99] M. Zoller. New molecular biology methods for protein engineering. , 1991, Current opinion in biotechnology.
[100] W. Cefalu,et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study , 2001, The Lancet.
[101] E. J. PubMed Citation,et al. An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction , 2009 .
[102] J. Reeve. Recombinant human parathyroid hormone , 2002, BMJ : British Medical Journal.
[103] K. Öberg. Neuroendocrine gastrointestinal tumours - a condensed overview , 1999 .
[104] E. Karita,et al. Postnatal transmission of human immunodeficiency virus type 1 from mother to infant. A prospective cohort study in Kigali, Rwanda. , 1991, The New England journal of medicine.
[105] C. Dobson,et al. Rational design of aggregation-resistant bioactive peptides: reengineering human calcitonin. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[106] B. Tarlatzis,et al. The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double-blind, randomized, prospective study. , 2006, Human reproduction.
[107] J. Belmont,et al. Enzyme-replacement therapy in mucopolysaccharidosis I. , 2001, The New England journal of medicine.
[108] Assent investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction , 2001, The Lancet.
[109] W. V. Mieghem. A comparison of continuous infusion of alteplase with double bolus administration for acute myocardial infarction: the continuous infusion versus double double bolus administration of alteplase , 1997 .
[110] Kenneth Koury,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[111] E. Ghigo,et al. The diagnosis of growth hormone deficiency (GHD) in adults. , 1995, The Journal of clinical endocrinology and metabolism.
[112] M. Levy,et al. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. , 2002, JAMA.
[113] A. Nissenson,et al. National Cooperative rHu Erythropoietin Study in patients with chronic renal failure--an interim report. The National Cooperative rHu Erythropoietin Study Group. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[114] C. Eng,et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome) , 2006, Genetics in Medicine.
[115] D. Goldenberg,et al. Carcinoembryonic antigen immunoscintigraphy complements mammography in the diagnosis of breast carcinoma , 2000, Cancer.
[116] L. Holle. Pegaspargase: An Alternative? , 1997, The Annals of pharmacotherapy.
[117] B H Perry,et al. Efficacy and safety of becaplermin (recombinant human platelet‐derived growth factor‐BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies , 1999, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.
[118] Orton,et al. INTRAVENOUS NESIRITIDE, A NATRIURETIC PEPTIDE, IN THE TREATMENT OF DECOMPENSATED CONGESTIVE HEART FAILURE , 2000 .
[119] P. Jungers,et al. RANDOMISED PLACEBO-CONTROLLED TRIAL OF HEPATITIS B SURFACE ANTIGEN VACCINE IN FRENCH HAEMODIALYSIS UNITS: I, MEDICAL STAFF , 1981, The Lancet.
[120] J. Hoefs,et al. Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial , 1997 .
[121] G. B. Dowling,et al. Vitamin D in cutaneous tuberculosis. , 1947, Lancet.
[122] Lawrence Blonde,et al. Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. , 2004, Diabetes care.
[123] R. Testa,et al. Long‐term follow up of chronic hepatitis C patients after α‐interferon treatment: A functional study , 2001, Journal of gastroenterology and hepatology.
[124] P. Meusers,et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. , 1991, The New England journal of medicine.
[125] N. Olsen,et al. New drugs for rheumatoid arthritis. , 2004, The New England journal of medicine.
[126] Thomas C. Südhof,et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25 , 1993, Nature.
[127] G. Albers,et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. , 2000, JAMA.
[128] Carl-Gustaf Rosen,et al. Process Economics of Animal Cell and Bacterial Fermentations: A Case Study Analysis of Tissue Plasminogen Activator , 1993, Bio/Technology.
[129] J. B. Collip,et al. Pancreatic extracts in the treatment of diabetes mellitus: preliminary report. 1922. , 1991, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[130] F. Mandelli,et al. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. , 1990, The New England journal of medicine.
[131] A. Laupacis. Changes in quality of life and functional capacity in hemodialysis patients treated with recombinant human erythropoietin. The Canadian Erythropoietin Study Group. , 1990, Seminars in nephrology.
[132] H. C. Coelingh Bennink,et al. Recombinant follicle-stimulating hormone (follitropin beta, Puregon) yields higher pregnancy rates in in vitro fertilization than urinary gonadotropins. , 1997, Fertility and sterility.
[133] David H. Miller,et al. A controlled trial of natalizumab for relapsing multiple sclerosis. , 2003, The New England journal of medicine.
[134] Timothy B. Stockwell,et al. The Sequence of the Human Genome , 2001, Science.
[135] S. Richards,et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. , 2004, The New England journal of medicine.
[136] G. Zych,et al. Osteogenic Protein-1 (Bone Morphogenetic Protein-7) in the Treatment of Tibial Nonunions: A Prospective, Randomized Clinical Trial Comparing rhOP-1 with Fresh Bone Autograft* , 2001, The Journal of bone and joint surgery. American volume.
[137] B. Coiffier,et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. , 1993, The New England journal of medicine.
[138] oseph,et al. PEGINTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS PEGINTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS , 2000 .
[139] D. Manninen,et al. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group. , 1990, JAMA.
[140] David Hunt,et al. ISIS-3 - A RANDOMIZED COMPARISON OF STREPTOKINASE VS TISSUE PLASMINOGEN-ACTIVATOR VS ANISTREPLASE AND OF ASPIRIN PLUS HEPARIN VS ASPIRIN ALONE AMONG 41,299 CASES OF SUSPECTED ACUTE MYOCARDIAL-INFARCTION , 1992 .
[141] L. Becker,et al. Antimyosin imaging in acute transmural myocardial infarctions: results of a multicenter clinical trial. , 1989, Journal of the American College of Cardiology.
[142] H. Fuchs,et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. , 1994, The New England journal of medicine.
[143] M. Ho,et al. Gaucher's disease: deficiency of 'acid' -glucosidase and reconstitution of enzyme activity in vitro. , 1971, Proceedings of the National Academy of Sciences of the United States of America.
[144] M. Haase. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. , 2002, Blood.
[145] S. Orkin,et al. Partial Correction of the Phagocyte Defect in Patients with X-Linked Chronic Granulomatous Disease by Subcutaneous Interferon Gamma , 1988 .
[146] F. Kabbinavar,et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[147] R. Schiffmann,et al. Enzyme Therapy in Type 1 Gaucher Disease: Comparative Efficacy of Mannose-Terminated Glucocerebrosidase from Natural and Recombinant Sources , 1995, Annals of Internal Medicine.
[148] Huub Schellekens,et al. Bioequivalence and the immunogenicity of biopharmaceuticals , 2002, Nature Reviews Drug Discovery.
[149] G. Albers,et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. , 1999, JAMA.
[150] R. Coler,et al. Evaluation of DPPD, a single recombinant Mycobacterium tuberculosis protein as an alternative antigen for the Mantoux test. , 2001, Tuberculosis.
[151] G. Rosen,et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. , 1996, Blood.
[152] T. Shea,et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers , 2017 .
[153] P. Watkins,et al. BIOSYNTHETIC HUMAN INSULIN IN THE TREATMENT OF DIABETES A Double-blind Crossover Trial in Established Diabetic Patients , 1982, The Lancet.
[154] R. Rosenberg. Actions and interactions of antithrombin and heparin. , 1975, The New England journal of medicine.
[155] T. Investigators,et al. A comparison of reteplase with alteplase for acute myocardial infarction , 1997 .
[156] I. Bernstein,et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[157] J. Soulillou,et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients , 1997, The Lancet.
[158] A. Phelan,et al. Intercellular delivery of functional p53 by the herpesvirus protein VP22 , 1998, Nature Biotechnology.
[159] M. Gordon. The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria , 2008 .
[160] J. Sninsky,et al. Evaluation of screened blood donations for human immunodeficiency virus type 1 infection by culture and DNA amplification of pooled cells. , 1991, The New England journal of medicine.
[161] J. Manning,et al. Treatment of hairy cell leukemia with recombinant α-interferon , 1986 .
[162] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[163] A. Friedman-kien. Management of condylomata acuminata with Alferon N injection, interferon alfa-n3 (human leukocyte derived). , 1995, American journal of obstetrics and gynecology.
[164] J. Burgess,et al. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments , 1990 .
[165] E. Braunwald,et al. RANDOMISED CONTROLLED TRIAL OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR VERSUS UROKINASE IN THE TREATMENT OF ACUTE PULMONARY EMBOLISM , 1988, The Lancet.
[166] K. Goa,et al. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. , 2003, Drugs.
[167] A. Boxer,et al. Debridement of dermal ulcers and decubiti with collagenase. , 1969, Geriatrics.
[168] J. Ritz,et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. , 2004, Blood.
[169] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[170] J. Mullane,et al. Effects of Pramlintide, an Analog of Human Amylin, on Plasma Glucose Profiles in Patients With IDDM: Results of a Multicenter Trial , 1997, Diabetes.
[171] D. Goodin,et al. Randomized, comparative study of interferon &bgr;-1a treatment regimens in MS: The EVIDENCE Trial , 2002 .
[172] E. Thorland,et al. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.
[173] R. D. de Man,et al. Long‐term follow‐up of alpha‐interferon treatment of patients with chronic hepatitis B , 2004, Hepatology.
[174] E. Gordon,et al. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. , 1994, Blood.
[175] M. E. Reid,et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin , 2002 .
[176] T. Wieman. Clinical efficacy of becaplermin (rhPDGF-BB) gel , 1998 .
[177] L. Wilkins. Randomized, comparative study of interferon β-1a treatment regimens in MS: The EVIDENCE Trial , 2003, Neurology.
[178] S. Malawista,et al. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium. , 1998, The New England journal of medicine.
[179] T. Quattrin,et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. , 2004, Diabetes care.
[180] P. Banks,et al. Does pancreatic enzyme supplementation reduce pain in patients with chronic pancreatitis: a meta-analysis. , 1997, The American journal of gastroenterology.
[181] E. Keeffe,et al. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group. , 1997, Hepatology.
[182] A D Shapiro,et al. Prospective, Randomised Trial of Two Doses of rFVIIa (NovoSeven) in Haemophilia Patients with Inhibitors Undergoing Surgery , 1998, Thrombosis and Haemostasis.
[183] A. Burgess,et al. Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor , 1992 .
[184] S. Boden,et al. The Use of rhBMP-2 in Interbody Fusion Cages: Definitive Evidence of Osteoinduction in Humans: A Preliminary Report , 2000, Spine.
[185] K. Doody,et al. Use of recombinant human chorionic gonadotropin in ovulation induction. , 2003, Fertility and sterility.
[186] Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. , 1995, Neurology.
[187] S. Sarker,et al. Effect of hyaluronidase on ocular motility and eyelid function in sub-Tenon's anaesthesia: randomised controlled trial , 2006, Eye.
[188] R. Fisher,et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[189] M. Atkins,et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. , 2000, The cancer journal from Scientific American.
[190] F. Wurm,et al. Large-scale transient expression in mammalian cells for recombinant protein production. , 1999, Current opinion in biotechnology.
[191] J. Arnout,et al. Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. , 1993, Blood.
[192] K. Lindsay. Therapy of hepatitis C: Overview , 1997, Hepatology.
[193] N. Sifontis. IMMUNOSUPPRESSIVE STRATEGIES IN SOLID ORGAN TRANSPLANTATION , 2006 .
[194] E. Estey,et al. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia , 2003, Cancer.
[195] Janice M. Reichert,et al. A guide to drug discovery: Trends in development and approval times for new therapeutics in the United States , 2003, Nature Reviews Drug Discovery.
[196] L. Hellgren. Cleansing properties of stabilized trypsin and streptokinase-streptodornase in necrotic leg ulcers , 2004, European Journal of Clinical Pharmacology.
[197] J. Byrd,et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. , 2002, Blood.
[198] R. Coler,et al. Cloning of a Mycobacterium tuberculosis gene encoding a purifed protein derivative protein that elicits strong tuberculosis-specific delayed-type hypersensitivity. , 2000, The Journal of infectious diseases.
[199] Lieschke Gj,et al. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2). , 1992, The New England journal of medicine.
[200] J. Kremer,et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. , 1999, The New England journal of medicine.
[201] C. Abildgaard,et al. Treatment of hemophilia with glycine-precipitated factor 8. , 1966, The New England journal of medicine.
[202] E. Ghigo,et al. The diagnosis of growth hormone deficiency in adults. , 1997, The Journal of clinical endocrinology and metabolism.
[203] D D Peterson,et al. A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study). , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[204] E. Braunwald,et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion , 1993, The Lancet.
[205] B. Chaitman,et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. , 1995, The New England journal of medicine.
[206] E. Schiff,et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. , 1990, The New England journal of medicine.
[207] J. Hecht,et al. A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer. , 2006, Clinical colorectal cancer.
[208] P. Rutgeerts,et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. , 1999, The New England journal of medicine.
[209] P. Wille-Jørgensen,et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. , 1997, The New England journal of medicine.
[210] R. Taillefer,et al. Acute thromboscintigraphy with (99m)Tc-apcitide: results of the phase 3 multicenter clinical trial comparing 99mTc-apcitide scintigraphy with contrast venography for imaging acute DVT. Multicenter Trial Investigators. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[211] Dieter Häussinger,et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.
[212] Paty Dw,et al. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. 1993 [classical article]. , 2001, Neurology.
[213] J. Egrie,et al. Development and characterization of novel erythropoiesis stimulating protein (NESP) , 2001, British Journal of Cancer.
[214] S. Garger,et al. Making an ally from an enemy: plant virology and the new agriculture. , 2002, Annual review of phytopathology.
[215] Susan Schneider,et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.
[216] B. Thiers. Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition , 2006 .
[217] D. Paty,et al. Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.
[218] R. Fleischmann,et al. Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis. , 2004, Journal of Rheumatology.
[219] T. Stijnen,et al. Growth hormone treatment in growth-retarded adolescents after renal transplant , 1994, The Lancet.
[220] A. Ghezzi,et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN) , 2002, The Lancet.
[221] S. Lamberts,et al. Drug therapy : octreotide , 1996 .
[222] J. Reginster,et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.
[223] M. Kosinski,et al. GARDASIL®: Prophylactic Human Papillomavirus Vaccine Development – From Bench Top to Bed‐side , 2007, Clinical pharmacology and therapeutics.
[224] C. Kessler,et al. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. , 2001, Blood.
[225] A. Buist,et al. Guidelines for the approach to the patient with severe hereditary alpha-1-antitrypsin deficiency. American Thoracic Society. , 1989, The American review of respiratory disease.
[226] J. Jankovic,et al. Therapeutic uses of botulinum toxin. , 1991, The New England journal of medicine.
[227] Scott D. Putney,et al. Improving protein therapeutics with sustained-release formulations , 1998, Nature Biotechnology.
[228] E. Karita,et al. Postnatal transmission of human immunodeficiency virus type 1 from mother to infant. , 1991, Disease markers.
[229] E. Colman,et al. A brief history of calcitonin , 2002, The Lancet.
[230] F. Werf. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial , 1999, The Lancet.
[231] R. Wilcox,et al. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence International Joint Efficacy Comparison of Thrombolytics , 1995, The Lancet.
[232] J. Katz,et al. Factor IX inhibitors and anaphylaxis in hemophilia B. , 1997, Haemophilia : the official journal of the World Federation of Hemophilia.
[233] C. Schmid,et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. , 1998, The New England journal of medicine.
[234] L. Rogers,et al. Streptokinase therapy for deep vein thrombosis: a comprehensive review of the English literature. , 1990, The American journal of medicine.
[235] G. Raghu,et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. , 2004, The New England journal of medicine.
[236] D. Goodin,et al. Randomized, comparative study of interferon β-1a treatment regimens in MS , 2002, Neurology.
[237] R. Rodriguiz,et al. Long-term treatment of osteopetrosis with recombinant human interferon gamma. , 1995, The New England journal of medicine.
[238] M. Dreyer,et al. Efficacy and safety of insulin glulisine in patients with type 1 diabetes. , 2005, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[239] G. Ebers,et al. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.
[240] U. Janssens,et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. , 1999, Circulation.
[241] N. Petrelli,et al. Use of carcinoembryonic antigen radioimmunodetection and computed tomography for predicting the resectability of recurrent colorectal cancer. , 1997, Annals of surgery.
[242] Daniel E. Otzen,et al. Protein drug stability: a formulation challenge , 2005, Nature Reviews Drug Discovery.
[243] R. Wilcox. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence: International Joint Efficacy Comparison of Thrombolytics , 1995 .
[244] L. Gullo,et al. Treatment of type II gastric carcinoid tumors with somatostatin analogues. , 2000, The New England journal of medicine.
[245] P. R. Frederick,et al. A randomized trial of intracoronary streptokinase in the treatment of acute myocardial infarction. , 1983, The New England journal of medicine.
[246] R. Levy,et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[247] A. Furlan,et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. , 2000, JAMA.
[248] A. Tashjian,et al. Teriparatide [Human PTH(1‐34)]: 2.5 Years of Experience on the Use and Safety of the Drug for the Treatment of Osteoporosis , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[249] Ma Dong,et al. Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .
[250] T. Tango,et al. A multicenter, randomized, controlled clinical trial of interferon alfacon-1 in comparison with lymphoblastoid interferon-alpha in patients with high-titer chronic hepatitis C virus infection. , 2002, Hepatology research : the official journal of the Japan Society of Hepatology.
[251] P. Fishman,et al. CuZn Superoxide Dismutase (SOD-1):Tetanus Toxin Fragment C Hybrid Protein for Targeted Delivery of SOD-1 to Neuronal Cells (*) , 1995, The Journal of Biological Chemistry.
[252] John C. Davis,et al. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. , 2002, The New England journal of medicine.
[253] T. Mor,et al. Edible plant vaccines: applications for prophylactic and therapeutic molecular medicine. , 2002, Trends in molecular medicine.
[254] R. Gelber,et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. , 1986, The New England journal of medicine.
[255] J. Garber,et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. , 1997, The New England journal of medicine.
[256] C. Lunan,et al. Efficacy and safety of a new, chromatographically purified rhesus (D) immunoglobulin. , 2004, European journal of obstetrics, gynecology, and reproductive biology.
[257] J. A. Scarlett,et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. , 2000, The New England journal of medicine.
[258] P. Mease,et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial , 2000, The Lancet.
[259] M. Houghton,et al. Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay , 1991, The Lancet.
[260] M. L. Gross. Ethics, Policy, and Rare Genetic Disorders: The Case of Gaucher Disease in Israel , 2002, Theoretical medicine and bioethics.
[261] J. Reichen,et al. Peginterferon alfa-2a in patients with chronic hepatitis C. , 2000, The New England journal of medicine.
[262] E. Topol,et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. , 2003, JAMA.
[263] E. Georgiev,et al. Collagenase in the Treatment of Dermal and Decubitus Ulcers , 1975, Journal of the American Geriatrics Society.
[264] L. Braverman,et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). , 1994, The Journal of clinical endocrinology and metabolism.
[265] M. S. Tewart,et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. , 2000 .
[266] A. Crandall,et al. A comparison of topical and retrobulbar anesthesia for cataract surgery. , 1996, Ophthalmology.
[267] F. Benfenati,et al. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin , 1992, Nature.
[268] Neal J Meropol,et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[269] D. Schoenfeld,et al. Ovulation and menstrual function of adolescent girls with central precocious puberty after therapy with gonadotropin-releasing hormone agonists. , 1992, The Journal of clinical endocrinology and metabolism.
[270] W. Busse,et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. , 2001, The Journal of allergy and clinical immunology.
[271] R. Kobayashi,et al. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. , 1987, The New England journal of medicine.
[272] T. Benyo,et al. Letter: Inhibition of labour by prostaglandin antagonists in impending abortion and preterm and term labour. , 1974, Lancet.
[273] K. Goa,et al. Alglucerase. A review of its therapeutic use in Gaucher's disease. , 1992, Drugs.
[274] R. Heine,et al. Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes , 2005, Annals of Internal Medicine.
[275] J. Dhainaut,et al. Protein C/activated protein C pathway: Overview of clinical trial results in severe sepsis , 2004, Critical care medicine.
[276] D. Kiel,et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. , 2000, The American journal of medicine.
[277] S. Richards,et al. UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response , 1995, The Lancet.
[278] K. Mergener,et al. A double‐blind, randomized, dose response study testing the pharmacological efficacy of synthetic porcine secretin , 2000, Alimentary pharmacology & therapeutics.
[279] L. Somogyi,et al. Comparison of Biologic Porcine Secretin, Synthetic Porcine Secretin, and Synthetic Human Secretin in Pancreatic Function Testing , 2003, Pancreas.
[280] John M. Woodley,et al. Fluid mixing in shaken bioreactors: Implications for scale-up predictions from microlitre-scale microbial and mammalian cell cultures , 2006 .
[281] S. Santavirta,et al. Recombinant Human Bone Morphogenetic Protein-2 for Treatment of Open Tibial Fractures: A Prospective, Controlled, Randomized Study of Four Hundred and Fifty Patients , 2002, The Journal of bone and joint surgery. American volume.
[282] R. Maguire,et al. Immunoscintigraphy in patients with colorectal, ovarian, and prostate cancer. Results with site‐specific immunoconjugates , 1993 .
[283] P. Toskes,et al. Protease-specific suppression of pancreatic exocrine secretion , 1984 .
[284] Jozef Arnout,et al. Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. , 1993 .
[285] G. Sibbald,et al. Recombinant human platelet‐derived growth factor‐BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open‐label clinical evaluation of efficacy , 2000, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.
[286] James B. Young. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial , 2002 .
[287] Kenneth J. Hillan,et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.
[288] S. Baron,et al. The interferons. Mechanisms of action and clinical applications. , 1991, JAMA.
[289] W. Chapman,et al. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. , 2007, Journal of the American College of Surgeons.
[290] J Ean,et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.
[291] M. Thakur,et al. Neutrophil-specific 99mTc-labeled anti-CD15 monoclonal antibody imaging for diagnosis of equivocal appendicitis. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[292] R. Dart,et al. Efficacy, safety, and use of snake antivenoms in the United States. , 2001, Annals of emergency medicine.
[293] M. Kaplan,et al. A RANDOMIZED CLINICAL TRIAL COMPARING OKT3 AND STEROIDS FOR TREATMENT OF HEPATIC ALLOGRAFT REJECTION , 1987, Transplantation.
[294] G. Burmester,et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. , 2003, Arthritis and rheumatism.
[296] H. Urnovitz,et al. Increased sensitivity of HIV-1 antibody detection , 1997, Nature Medicine.
[297] J. Stockman. AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP , 2008 .
[298] J. Duchin,et al. Comparison of sensitivities to two commercially available tuberculin skin test reagents in persons with recent tuberculosis. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[299] R. Fisher,et al. A phase 2 trial of CHOP chemotherapy followed by tositumomab / iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma : Southwest Oncology Group Protocol S 9911 , 2003 .
[300] M. Andreeff,et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[301] M. Ranke,et al. Testing with growth hormone-releasing factor (GRF(1–29)NH2) and somatomedin C measurements for the evaluation of growth hormone deficiency , 1986, European Journal of Pediatrics.
[302] G. Bakale,et al. Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers. , 2000, Urology.
[303] S. Tyring,et al. Interferons in human papillomavirus infections. , 1994, Antiviral research.
[304] J. Dambrosia,et al. Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. , 1991, The New England journal of medicine.
[305] F. Montemurro,et al. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[306] R. Fisher,et al. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. , 2003, Blood.
[307] M. Cairo,et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. , 2001, Blood.
[308] B. Weissmann,et al. The defect in the Hurler and Scheie syndromes: deficiency of -L-iduronidase. , 1972, Proceedings of the National Academy of Sciences of the United States of America.
[309] Gerald R. Williams,et al. Complications of Thermal Capsulorrhaphy of the Shoulder , 2001, The Journal of bone and joint surgery. American volume.
[310] R. Levy,et al. Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[311] N Lotan,et al. Large porous particles for pulmonary drug delivery. , 1997, Science.